Cerebrolysin, a neuropeptide preparation, mimics and modulates the brain's own neurotrophic factors, showing clinical benefits across dementia, stroke, and traumatic brain injury.
5 neurotrophic factorsCerebrolysin modulates the expression of NGF, IGF-1, BDNF, VEGF, and TNF-α — engaging multiple neuroprotective pathways simultaneously
What the researchers found
Neurotrophic factors (NTFs) — including NGF, IGF-1, BDNF, VEGF, and TNF-α — are deeply involved in the pathophysiology of dementia, stroke, and traumatic brain injury, and represent high-value therapeutic targets. The neuropeptide preparation Cerebrolysin has been shown to mimic the activities of these NTFs and modulate the expression levels of endogenous neurotrophic factors.
Cerebrolysin demonstrated beneficial effects in both in vitro studies and clinical trials across all three conditions, acting through neuroplasticity, neurogenesis, angiogenesis, and anti-inflammatory pathways. The review emphasizes that these NTFs don't work in isolation — their signaling networks interact, and Cerebrolysin appears to engage multiple pathways simultaneously.
Why it matters
Dementia, stroke, and TBI are among the leading causes of disability worldwide, and treatment options remain limited. This review maps the neurotrophic factor network underlying these conditions and positions Cerebrolysin as a multi-target neuropeptide therapy — an approach that may be more effective than targeting a single growth factor, given how interconnected these signaling pathways are.
The numbers in context
5 NTFs reviewed (NGF, IGF-1, BDNF, VEGF, TNF-α) · 3 conditions covered (dementia, stroke, TBI) · 4 mechanisms: neuroplasticity, neurogenesis, angiogenesis, inflammation
How the study worked
This is a comprehensive narrative review that synthesizes published preclinical and clinical evidence on five neurotrophic factors and their roles in dementia, stroke, and TBI. The review evaluates the biochemistry, signaling networks, and therapeutic potential of these NTFs, with a focus on how Cerebrolysin modulates their expression and activity.
Who was studied
Review covering in vitro studies, animal models, and clinical trials in patients with dementia, stroke, and traumatic brain injury
What this study cannot tell us
As a narrative review, the paper synthesizes existing evidence rather than generating new data. The clinical evidence for Cerebrolysin varies in quality across the three conditions, and some of the clinical trials reviewed may have limitations in design or sample size. The review focuses on selected NTFs rather than the complete neurotrophic landscape.
How to read the evidence
This review synthesizes both preclinical and clinical evidence across three neurological conditions. While clinical trials support Cerebrolysin's benefits, the evidence varies in quality, and this is a narrative rather than systematic review.
When this study was published
Published in 2023 in Medicinal Research Reviews, this is a recent and comprehensive overview of the neurotrophic factor landscape and Cerebrolysin's role within it.
The bigger picture
Most drug development targets a single molecule or pathway, but brain diseases involve complex networks of interacting growth factors. Cerebrolysin's multi-target approach — engaging neuroplasticity, neurogenesis, angiogenesis, and inflammation simultaneously — represents a different therapeutic philosophy that may better match the complexity of neurological disorders.
Questions still open
- Which neurotrophic factor pathway is most critical for each condition — dementia, stroke, or TBI?
- Can Cerebrolysin's multi-target approach outperform single-target therapies in head-to-head clinical trials?
- What is the optimal treatment window for Cerebrolysin after acute brain injury?
Common questions
What is Cerebrolysin and how does it work?
What conditions has Cerebrolysin been studied for?
Read the original research
Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin.
Medicinal research reviews, 43(5), 1668-1700
Citation
Rejdak, Konrad; Sienkiewicz-Jarosz, Halina; Bienkowski, Przemyslaw; Alvarez, Anton. (2023). Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin.. Medicinal research reviews, 43(5), 1668-1700. https://doi.org/10.1002/med.21960